“Mildly Suspicious” Thyroid Nodule(TIRADS 3 / TR3): What That Actually Means

Written by John P. Sabra, MD FACS
Updated May 2026

Educational only. This article is not medical advice. Always consult your physician about your individual situation.

You got your thyroid ultrasound results. You opened the report in your patient portal, scanned down the page, and landed on two words: mildly suspicious. Or perhaps you saw a score — TIRADS 3, or TR3 — and went straight to the internet trying to understand what it means. If that is where you are right now, this article is written for you.

Here is the most important sentence on this page: “mildly suspicious” does not mean likely cancer. It is a standardized descriptor that radiologists use to flag nodules that have a small number of features worth monitoring — not features that indicate disease. The malignancy risk associated with a TR3 nodule is under 5%, which means more than 95 out of 100 TR3 nodules are benign.

TIRADS Is a Framework, Not a Verdict

TIRADS stands for Thyroid Imaging Reporting and Data System. It is a scoring framework developed by the American College of Radiology to give radiologists a standardized way to communicate risk and guide clinical decision-making around thyroid nodules. The scale runs from TR1 — essentially normal thyroid tissue — to TR5, which carries the highest level of concern.

TIRADS guidelines represent the best available evidence applied across a large population of patients. They are carefully developed, regularly updated, and clinically useful. But they are guidelines, not rules. A TIRADS score tells your physician where to start a conversation — it does not tell them what to do. Your age, your other health conditions, your medications, your goals, and what a procedure would actually mean for your daily life are all part of the picture that no scoring system can capture.

What “Mildly Suspicious” Actually Means — and What It Doesn’t

When a radiologist writes “mildly suspicious” on your report, they are not expressing a clinical concern about you personally. They are using a standardized descriptor that corresponds to the TR3 category — a nodule that has one or more features that place it slightly above the baseline, but none of the high-risk features that would push it into TR4 or TR5 territory.

The word “suspicious” in radiology carries a very different weight than it does in everyday conversation. In TIRADS terminology, it is simply the name of a tier — one that, at level 3, carries a malignancy risk of approximately 5% or less. If 100 patients with TR3 nodules all had biopsies, roughly 95 of them would come back completely benign.

Where TR3 Sits in the TIRADS Picture

Level	Description	Malignancy Risk	ACR Guideline FNA Threshold
TR1	Benign	0%	Not typically indicated
TR2	Not suspicious	<1%	Not typically indicated
TR3 ▶	Mildly suspicious	~5%	Consider FNA at ≥ 2.5 cm — patient factors may shift this
TR4	Moderately suspicious	6–17%	Consider FNA at ≥ 1.5 cm
TR5	Highly suspicious	20–35%+	Consider FNA at ≥ 1.0 cm

The Ultrasound Features That Create a TR3 Score

Ultrasound Feature	Typical TR3 Finding	Why It Matters
Composition	Solid or partially solid	Solid tissue has more cells to evaluate; not itself alarming at TR3
Echogenicity	Isoechoic or hyperechoic	Same brightness or brighter than surrounding thyroid — generally reassuring
Shape	Wider than tall	Taller-than-wide shape is a higher-risk feature — its absence keeps risk low
Margins	Smooth or ill-defined	Irregular or spiculated margins would push the score higher
Echogenic foci	None, or large comet-tail artifacts	Absence of microcalcifications is one of the most reassuring TR3 features

Size, the FNA Threshold, and Why “Large” Doesn’t Mean “Dangerous”

The ACR guideline for TR3 nodules is to consider FNA biopsy when the nodule reaches 2.5 cm or larger. Below that threshold, the standard approach is surveillance: follow-up ultrasound at years 1, 3, and 5.

TR3 nodule at 1.5 cm: Surveillance is the standard recommendation. Follow-up ultrasound at 1 year, then at 3 and 5 years if stable. No biopsy indicated under current guidelines for most patients.
TR3 nodule at 2.5 cm or larger: Biopsy is generally considered. A 2.5 cm TR3 nodule still carries a malignancy risk under 5% — the threshold exists to provide a definitive answer, not because size alone elevates the risk.
Large TR3 nodule at 3 cm or more: Even at this size, the TR3 category reflects a low-suspicion feature profile. Size may become relevant for other reasons, including symptoms, cosmetic concern, or candidacy for RFA.

What the Typical Management Pathway Looks Like

Nodule below 2.5 cm, no suspicious features, no symptoms: Surveillance with repeat ultrasound at 1 year. If stable, follow-up continues at years 3 and 5. If the nodule shows no significant growth or change over five years, many physicians will consider it behaviorally benign and reduce monitoring frequency.
Nodule at or above 2.5 cm, or with new symptoms: FNA biopsy is generally considered. The biopsy is a brief, well-tolerated office procedure that takes 20 to 30 minutes. In the large majority of TR3 patients who have it, the result comes back benign.
Nodule with significant interval growth: Significant growth is defined as a 20% increase in at least two nodule dimensions with a minimum 2 mm increase, or a 50% increase in volume. If this threshold is met, repeat biopsy is typically recommended.

The Bottom Line for TR3 Patients

A TR3 result represents a very low level of clinical concern. The associated malignancy risk is under 5%, the management pathway is typically surveillance rather than immediate intervention, and the large majority of TR3 nodules that are eventually biopsied come back benign.

What it does mean is that this is the right moment to make sure you have the right physician looking at your specific result. Not because the finding is urgent, but because a TR3 nodule on surveillance benefits from a specialist’s eye — someone who reviews ultrasound reports like yours regularly and can build a care plan around your complete picture rather than a population-level guideline.

References

This article was written by John P. Sabra, MD FACS and is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician. TIRADS categories are clinical guidelines — not mandatory rules. Individual nodule characteristics, patient health history, age, risk factors, and clinical judgment all determine the appropriate management for every patient.

Ready to Talk to a Specialist?

A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.

Find a Thyroid Specialist Near You →